InvestorsHub Logo
Followers 20
Posts 5350
Boards Moderated 0
Alias Born 01/04/2012

Re: silvr_surfr post# 13860

Sunday, 06/05/2022 6:18:12 AM

Sunday, June 05, 2022 6:18:12 AM

Post# of 14907
Silvr, the 5,246 participant 5-year men's trial led by AbbVie is scheduled to be completed this month.

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE)

The 700,000 participant retrospective study is scheduled to be completed in November of this year.

Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes

As you stated, I believe AbbVie will strategically time the publishing of results for both men and women. And yes, ANIP is well positioned from the female perspective. If the data is equally compelling as Bayer's release, I expect an influx of investors into testosterone related stocks just as you saw Covid related stocks benefit over the last couple of years.

Should make for an an entertaining year.

JMHO
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News